Virus-specific CD8+ T cells that differentiate in the context of resolved versus persisting
infections exhibit divergent phenotypic and functional characteristics, which suggests that …

The PD-1 pathway is a cornerstone in immune regulation. While the PD-1 pathway has
received considerable attention for its role in contributing to the maintenance of T cell …

Overcoming immune-mediated resistance to PD-1 blockade remains a major clinical
challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined …

Background T cells form the major component of anti-tumor immunity. A deeper
understanding of T cell exhaustion (TEX) heterogeneity within the tumor microenvironment …

Background: Gastric cancer remains the third most common cause of cancer-related death
worldwide. The development of novel therapeutic strategies for gastric cancer requires a …

Colorectal cancers (CRCs) deficient in DNA mismatch repair (dMMR) contain abundant
CD8+ tumor-infiltrating lymphocytes (TILs) responding to the abundant neoantigens from …

The microenvironment of lymph node metastasized tumors (LNMT) determines tumor
progression and response to therapy, but a systematic study of LNMT is lacking. Here, we …

CD8+ T cell activation via immune checkpoint blockade (ICB) is successful in microsatellite
instable (MSI) colorectal cancer (CRC) patients. By comparison, the success of …

The past decade has witnessed significant advances in the systemic treatment of advanced
hepatocellular carcinoma (HCC). Nevertheless, the newly developed treatment strategies …

Immune-related adverse events (irAEs) are a notable complication of PD-1 cancer
immunotherapy. A better understanding of how these iatrogenic diseases compare with …